Cortexyme, Inc.(NASDAQ : CRTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.11%||64.40||1.0%||$544.24m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.04%||272.45||1.9%||$492.78m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.78%||688.78||2.6%||$437.93m|
|SNSS||Sunesis Pharmaceuticals, Inc.||2.86%||2.16||0.7%||$150.99m|
|EXAS||EXACT Sciences Corp.||6.46%||53.08||17.7%||$136.48m|
|TXG||10X Genomics, Inc.||11.94%||53.01||0.0%||$106.48m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.35%||80.71||4.2%||$96.76m|
|CRSP||CRISPR Therapeutics AG||4.20%||57.55||0.6%||$83.77m|
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.